Ribociclib

Major

Ribociclib Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Ribociclib Granisetron Injection Granisol An increased risk of QT interval prolongation Details Ribociclib Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Ribociclib Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Ribociclib Ibrexafungerp Brexafemme Increased ibrexafungerp exposure Details Ribociclib Ibrutinib Imbruvica Increased ibrutinib exposure Details Ribociclib Infigratinib Truseltiq Increased infigratinib plasma concentrations Details Ribociclib Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Ribociclib Irinotecan Camptosar Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Ribociclib Irinotecan Injection Camptosar Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Ribociclib Irinotecan Lipid Complex Injection Onivyde® Increased irinotecan liposome exposure and an increased irinotecan liposome active metabolite exposure Details Ribociclib Istradefylline Nourianz Increased istradefylline exposure Details Ribociclib Ixabepilone Injection IXEMPRA Increased ixabepilone exposure and increase in the incidence and severity of adverse reactions Details Ribociclib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Ribociclib Leniolisib Joenja Increased leniolisib exposure Details Ribociclib Lenvatinib Lenvima Increased risk of QT-interval prolongation Details Ribociclib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Ribociclib Levofloxacin Levaquin An increased risk of QT interval prolongation Details Ribociclib Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Ribociclib Loperamide Diamode Increased loperamide exposure, an increased risk of loperamide-related adverse effects and an increased risk of QT interval prolon... Details Ribociclib Lumateperone Caplyta Increased lumateperone exposure and an increased risk of lumateperone-related adverse reactions Details Ribociclib Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Ribociclib Macitentan Opsumit Increased macitentan exposure Details Ribociclib Maraviroc Selzentry Increased maraviroc exposure Details Ribociclib Mefloquine Lariam® An increased risk of QT interval prolongation Details Ribociclib Methylergonovine Methergine Increased methylergonovine exposure and an increased risk of vasospasm, cerebral ischemia and/or ischemia of extremities Details Ribociclib Metronidazole Flagyl An increased risk of QT interval prolongation Details Ribociclib Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Ribociclib Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Ribociclib Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Ribociclib Midostaurin Rydapt Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Mirvetuximab Soravtansine-Gynx Injection Elahere Increased unconjugated DM4 exposure and an increased risk of mirvetuximab soravtansine-gynx adverse reactions Details Ribociclib Mitapivat Aqvesme Increased mitapivat exposure, an increased risk of mitapivat-related adverse reactions and reduced CYP3A substrate exposure Details Ribociclib Moxifloxacin Avelox An increased risk of QT interval prolongation Details Ribociclib Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Ribociclib Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Ribociclib Neratinib Nerlynx Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Ribociclib Nifedipine Adalat® Increased NIFEdipine exposure and an increased risk of hypotension, bradycardia, or acute renal injury Details Ribociclib Octreotide Bynfezia An increased risk of QT interval prolongation Details Ribociclib Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details